BioSpace News Archive

The global market for automated endoscope reprocessors market is growing at a stellar rate and is likely to continue during the forecast period 2018 – 2028, owing to aggressive growth in the healthcare sector.

Genenta Science, a clinical-stage biotechnology company pioneering the development of a hematopoietic stem cell gene therapy for cancer, announces that Richard Slansky is appointed as Chief Financial Officer and proposes Anthony Marucci as independent member of the Board of Directors.

Masimo announced the findings of a study published in the Journal of Applied Physiology in which Dr. Marina García-de-Acilu and colleagues at the Vall d’Hebron University Hospital in Barcelona evaluated the utility of Masimo PVi® as a noninvasive method of predicting preload responsiveness in patients treated with nasal high-flow therapy.

Camurus AB announced that the Australian regulatory agency, the Therapeutic Goods Administration, has approved key label updates to Buvidal® Weekly and Buvidal® Monthly modified-release solutions for injection.

BioRestorative Therapies, Inc., a life sciences company focused on stem cell-based therapies, announced that it has filed its Annual Report on Form 10-K for the year ended December 31, 2020 and, as a result, is now current in its SEC periodic filings.

Professor Tsukasa Kumai, member of the Japan’s Olympic Committee Medical and Scientific Staff, will lead RepliCel’s Tendon Regeneration Clinical Testing in Japan

Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced an agreement with Gavi, the Vaccine Alliance to supply up to 500 million doses of the COVID-19 Vaccine Moderna, including an initial 34 million doses to be delivered in the fourth quarter of 2021.

Teleflex Incorporated announced that its Board of Directors declared a quarterly cash dividend of thirty-four cents per share of common stock.

ChromaDex Corp. is scheduled to participate in a virtual presentation at the Benzinga Small Cap Conference on Thursday, May 13, 2021 at 11:30am ET.

Avivagen Inc. is pleased to announce that Meyenberg International Group, Avivagen’s consultant in Mexico, has entered into a contract which secures a four tonne per month recurring order for OxC-beta™ Livestock in Mexico.